PCVX — Vaxcyte Inc. stock price and chart

Share this page

PCVX

$63.62-2.53%

as of close, Oct 16, 2026

☾ AH $63.62 -2.53%

Vaxcyte Inc.Stock · HealthcareRussell 2000 0.2%Nasdaq Composite 0.02%US Stock Market 0.01%Russell 3000 0.01%

PeersMRNALLYMDTUNHJNJTMO

Technical analysis2

Overlay lines0

Addendum charts0

Available history since Jun 17, 2020

VolumeEEEE

20202022202320252026

20.030.040.050.060.070.080.090.0100.0110.0020.0M$63.62

2026-10-16

Price$63.62

MA20$59.26

MA50$56.24

Vol7.2M

What would $1,000 invested in PCVX be worth today? →

PCVX returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $63.62
YTD price return: +37.88%
YTD total return: +37.88%
Next earnings: Nov 3, 2026
Market cap: 9.5B2020-06 1.6B2026-10 9.5B+488.0% over the window
Enterprise value: 8.1B
Shares outstanding: 148.8M2019-12 4.1M2026-06 148.8M+3565.2% over the window
52W low: $39.87
52W high: $90.75
From 52W high: -29.90%
From 52W low: +59.57%
52W range: 47%

Volume

Rel volume: 1.12×
30D volume: 2.9M
30D $ vol: 189.2M

Fundamentals

EPS (ttm): -$7.652020-12 -$3.022026-06 -$7.65+153.2% over the window
FCF (ttm): -894.1M2018-12 -32.2M2026-06 -894.1M+2673.4% over the window
FCF/share: -$6.012019-12 -$11.912026-06 -$6.01-49.5% over the window
Book value/share: $18.532019-06 -$20.072026-06 $18.53-192.4% over the window
ROE: -38.59%2020-06 -19.2%2026-06 -38.6%+101.5% over the window
ROA: -33.91%2019-12 -76.5%2026-06 -33.9%-55.7% over the window
Current ratio: 5.722019-12 5.582026-06 5.72+2.5% over the window

Growth (CAGR, ttm) · 10Y

Shares: +14.63%2025-06-30 → 2026-06-30129.8M → 148.8M (+14.6% total)+16.61%2023-06-30 → 2026-06-3093.8M → 148.8M (+58.6% total)+23.32%2021-06-30 → 2026-06-3052.2M → 148.8M (+185.1% total)n/a

Per-share growth (CAGR, ttm) · 10Y

Book value/share: -21.67%2025-06-30 → 2026-06-30$23.66 → $18.53 (-21.7% total)+6.66%2023-06-30 → 2026-06-30$15.27 → $18.53 (+21.3% total)+25.00%2021-06-30 → 2026-06-30$6.07 → $18.53 (+205.1% total)n/a
Price: +45.99%2025-10-16 → 2026-10-16$43.59 → $63.62 (+46.0% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+10.71%2023-10-16 → 2026-10-16$46.88 → $63.62 (+35.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+21.11%2021-10-15 → 2026-10-16$24.41 → $63.62 (+160.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.n/a
Total return: +45.99%2025-10-16 → 2026-10-16$43.59 → $63.62 (+46.0% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+10.71%2023-10-16 → 2026-10-16$46.88 → $63.62 (+35.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+21.11%2021-10-15 → 2026-10-16$24.41 → $63.62 (+160.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.n/a

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: -8.3×2020-06 -21.932026-10 -8.89-59.4% over the window
Fwd P/E: -9.0×
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 3.4×2020-06 4.202026-10 3.43-18.3% over the window
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: -9.44%2020-06 -3.0%2026-06 -10.3%+246.0% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 148.8M ÷ 129.8M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -14.63%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-14.63%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($4.2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -14.63%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($9.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2020-06 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($9.5B). Same caveat as the cash buyback yield.: 0.00%2020-06 0.0%2026-06 0.0%

Vs own 10Y history

P/B: 42nd

Bar = where today’s multiple sits in PCVX’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-16#

-2.53%

-10.87%

+8.25%

+13.53%

YTD

+37.88%

+45.95%

+160.63%

Financial statements

Open full PCVX financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+10.48%	+0.43%
JNJ	Johnson & Johnson	-4.38%	+0.90%
ABBV	AbbVie Inc.	+8.73%	+0.71%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+6.97%	-1.29%
MRK	Merck & Co. Inc.	+0.72%	+0.52%
NVS	Novartis AG	+8.59%	+0.16%
TMO	Thermo Fisher Scientific Inc.	+6.41%	-0.93%
AMGN	Amgen Inc.	+14.92%	-0.35%

PCVX — Vaxcyte Inc. price, chart and key statistics